Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Feb;34(2):206–209. doi: 10.1128/aac.34.2.206

5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro.

J Bouchard 1, M C Walker 1, J M Leclerc 1, N Lapointe 1, R Beaulieu 1, L Thibodeau 1
PMCID: PMC171557  PMID: 1691617

Abstract

Chemotherapeutic agents which affect the integration, stability, or inducibility of the human immunodeficiency virus (HIV) provirus would have considerable value in treating acquired immunodeficiency syndrome. Two nucleoside analogs of cytosine, 5-azacytidine and 5-azadeoxycytidine, which seem to have such value because of their capabilities to affect both the stability and the methylation patterns of the nucleic acids into which they are incorporated, were tested for their ability to inhibit the replication of HIV type 1 (HIV-1) in human CEM T cells in vitro. 5-Azadeoxycytidine (1 microM) completely inhibited HIV replication in CEM cells, by the criteria of reduced viral antigen expression and decreased supernatant reverse transcriptase activity, with little toxicity for the treated cells. 5-azacytidine (1 microM) also inhibited HIV replication, but less effectively. When added 2 or more h after CEM cells were infected with HIV-1, both 5-azacytosine derivatives were less effective than they were when added at the time of infection. Even 2 h of exposure to 5-azadeoxycytidine was sufficient for inhibition of HIV replication. Although long exposure to either analog at concentrations of 1 microM would result in pronounced cellular cytotoxicity, the the fact that short exposures to the same dose of drug inhibit HIV replication but are not toxic for the cells implies that cellular toxicity itself is not an important mechanism of the antiviral action of the analogs.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bednarik D. P., Mosca J. D., Raj N. B. Methylation as a modulator of expression of human immunodeficiency virus. J Virol. 1987 Apr;61(4):1253–1257. doi: 10.1128/jvi.61.4.1253-1257.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bouchard J., Leclerc J. M., Thibodeau L., Walker M. C. 5-Aza-cytosine derivative chemotherapy in AIDS. Ann Inst Pasteur Virol. 1988 Jul-Sep;139(3):309–317. doi: 10.1016/s0769-2617(88)80047-9. [DOI] [PubMed] [Google Scholar]
  3. Bouchard J., Momparler R. L. Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol. 1983 Jul;24(1):109–114. [PubMed] [Google Scholar]
  4. Cedar H. DNA methylation and gene activity. Cell. 1988 Apr 8;53(1):3–4. doi: 10.1016/0092-8674(88)90479-5. [DOI] [PubMed] [Google Scholar]
  5. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  6. Gill P. S., Rarick M., Brynes R. K., Causey D., Loureiro C., Levine A. M. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987 Oct;107(4):502–505. doi: 10.7326/0003-4819-107-4-502. [DOI] [PubMed] [Google Scholar]
  7. Hirsch M. S. AIDS commentary. Azidothymidine. J Infect Dis. 1988 Mar;157(3):427–431. doi: 10.1093/infdis/157.3.427. [DOI] [PubMed] [Google Scholar]
  8. Jones P. A. Effects of 5-azacytidine and its 2'-deoxyderivative on cell differentiation and DNA methylation. Pharmacol Ther. 1985;28(1):17–27. doi: 10.1016/0163-7258(85)90080-4. [DOI] [PubMed] [Google Scholar]
  9. Kitamura T., Takano M., Hoshino H., Shimotohno K., Shimoyama M., Miwa M., Takaku F., Sugimura T. Methylation pattern of human T-cell leukemia virus in vivo and in vitro: pX and LTR regions are hypomethylated in vivo. Int J Cancer. 1985 May 15;35(5):629–635. doi: 10.1002/ijc.2910350510. [DOI] [PubMed] [Google Scholar]
  10. Mitsuya H., Broder S. Strategies for antiviral therapy in AIDS. 1987 Feb 26-Mar 4Nature. 325(6107):773–778. doi: 10.1038/325773a0. [DOI] [PubMed] [Google Scholar]
  11. Momparler R. L. Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther. 1985;30(3):287–299. doi: 10.1016/0163-7258(85)90053-1. [DOI] [PubMed] [Google Scholar]
  12. Veselý J. Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells. Pharmacol Ther. 1985;28(2):227–235. doi: 10.1016/0163-7258(85)90012-9. [DOI] [PubMed] [Google Scholar]
  13. Yarchoan R., Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med. 1987 Feb 26;316(9):557–564. doi: 10.1056/NEJM198702263160925. [DOI] [PubMed] [Google Scholar]
  14. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES